A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06047860 |
|
Recruitment Status :
Recruiting
First Posted : September 21, 2023
Last Update Posted : September 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Advanced Solid Tumor Refractory Tumor | Radiation: Radiotherapy Drug: PD-1/PD-L1 inhibitor Drug: Granulocyte-macrophage colony-stimulating factor subcutaneous injection Drug: Interleukin 2 subcutaneous injection Drug: Endostatin | Phase 2 |
Radiotherapy:
Start radiotherapy on the first day of treatment, as described in 6.2 above;
GM-CSF treatment:
GM-CSF 200 μg on the first day of treatment, administered subcutaneously daily for 7 days; IL-2 treatment. 2 million IU of IL-2 on the day after GM-CSF, administered subcutaneously daily for 7 days;
Immunotherapy:
PD-1/PD-L1 inhibitors within one week of radiotherapy;
Recombinant human vascular endothelial inhibitor (Endo):
Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h starting on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
Maintenance treatment phase:
Maintenance with PD-1/PD-L1 inhibitor in combination with recombinant human vascular endothelial inhibitor (Endo) until progression or intolerable side effects.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 30 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor (Endo) in Combination With Bragg Treatment for Advanced Refractory Non-small Cell Lung Cancer |
| Actual Study Start Date : | June 16, 2023 |
| Estimated Primary Completion Date : | December 30, 2024 |
| Estimated Study Completion Date : | December 31, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Intervention group
M-CSF 200 μg administered subcutaneously daily for 7 days on the first day of treatment; IL-2 2 million IU administered subcutaneously daily for 7 days the day after GM-CSF; PD-1/PD-L1 inhibitor within one week of radiotherapy; Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h starting on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy. Maintenance treatment phase: Maintenance with PD-1/PD-L1 inhibitor in combination with recombinant human vascular endothelial inhibitor (Endo) until progression or intolerable side effects. |
Radiation: Radiotherapy
hypofractionated radiotherapy/SBRT
Other Name: SBRT Drug: PD-1/PD-L1 inhibitor PD-1/PD-L1 inhibitor within one week of radiotherapy
Other Name: PD-1/PD-L1 antibody Drug: Granulocyte-macrophage colony-stimulating factor subcutaneous injection IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
Other Name: GM-CSF Drug: Interleukin 2 subcutaneous injection IL-2 2 million IU the day after the end of GM-CSF, administered subcutaneously daily for 7 days;
Other Name: IL-2 Drug: Endostatin Recombinant human vascular endothelial inhibitor (Endo) 210 mg CIV72h was started on the first day of treatment, every 21 days for a minimum of ≥ 2 cycles of this combination therapy.
Other Name: Endo |
- overall response rate(ORR) [ Time Frame: six weeks ]ORR is defined as the proportion of patients who have a partial (PR) or complete response (CR) to therapy among the total number of evaluable patients.
- Disease control rate (DCR) [ Time Frame: six weeks ]the percentage of patients who have achieved complete response (CR), partial response (PR) and stable disease (SD)
- Progression free survival (PFS) [ Time Frame: six weeks ]The time from commencement of treatment to disease progression or death from any cause.
- Overall survival (OS) [ Time Frame: six weeks ]The time from the first day of enrollment to death from any cause.
- Incidence of adverse events [ Time Frame: six weeks ]the rate of AE
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients aged 18-75 years;
- Patients enrolled must be eligible for patients with recurrent or metastatic advanced non-small cell lung cancer, with a clear pathological diagnosis report or history of disease, with guidelines that do not clearly recommend standard treatment regimens or who are unable to tolerate standard treatment regimens, and with clear measurable metastatic lesions (>1cm);
- No congestive heart failure, unstable angina, or unstable arrhythmia within the last 6 months.
- Patient activity status score of 0-3 on the Eastern Cooperative Oncology Group (ECOG) scale with life expectancy assessed at ≥3 months.
- No previous severe haematopoietic, cardiac, pulmonary, hepatic or renal abnormalities and immunodeficiency.
- Absolute T-lymphocyte values ≥ 0.5 times the lower limit of normal and neutrophils ≥ 1.0 x 109/L; AST and ALT ≤ 3.0 times the upper limit of normal (≤ 5.0 times the upper limit of normal for hepatocellular carcinoma/metastatic liver cancer); creatinine ≤ 3.0 times the upper limit of normal, 1 week prior to enrollment.
- Patients must have the ability to understand and voluntarily sign the informed consent form.
Exclusion Criteria:
- Pregnant or breastfeeding women;
- Persons with a history of other malignant disease in the last 5 years, except cured skin cancer and carcinoma in situ of the cervix;
- Persons with a history of uncontrolled epilepsy, central nervous system disorders or psychiatric disorders whose clinical severity, as judged by the investigator, may prevent the signing of an informed consent or affect the patient's compliance with drug therapy;
- Clinically significant (i.e., active) cardiac disease such as symptomatic coronary artery disease, New York Heart Association (NYHA) class II or worse congestive heart failure or severe arrhythmias requiring pharmacological intervention, or a history of myocardial infarction within the last 12 months;
- Persons requiring immunosuppressive therapy for organ transplantation;
- Known major active infection or, in the judgement of the investigator, major haematological, renal, metabolic, gastrointestinal, endocrine dysfunction or metabolic disorders, or other serious uncontrolled concomitant disease;
- Hypersensitivity to any investigational drug component;
- Persons with a history of immunodeficiency, including those who have tested positive for HIV or have other acquired or congenital immunodeficiency diseases, or a history of organ transplantation, or other immune-related diseases requiring long-term oral hormone therapy
- Persons with active tuberculosis infection;
- Those with interstitial lung disease or non-infectious pneumonia that may prevent the assessment of pulmonary toxicity associated with the study or the manager;
- Other conditions that, in the opinion of the investigator, are not suitable for enrolment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06047860
| Contact: Liyuan Zhang | 0512-67784829 | zhangliyuan126@126.com |
| China | |
| The Second Affiliated Hospital of SchoowUniversity | Recruiting |
| Suzhou, China, 215004 | |
| Contact: Pengfei Xing 13862069147 drxingpengfei@126.com | |
| Responsible Party: | Second Affiliated Hospital of Soochow University |
| ClinicalTrials.gov Identifier: | NCT06047860 |
| Other Study ID Numbers: |
JD-LK-2022-173-01 |
| First Posted: | September 21, 2023 Key Record Dates |
| Last Update Posted: | September 21, 2023 |
| Last Verified: | September 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Lung Diseases Respiratory Tract Diseases Interleukin-2 Endostatins Molgramostim Immune Checkpoint Inhibitors |
Sargramostim Antineoplastic Agents Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Growth Inhibitors Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological |